ReShape Lifesciences enters merger with Vyome Therapeutics, sells assets to Biorad for $5.16M

Vyome Holdings, Inc

Q2 revenue $2.0M (-12.8% YoY); six-month revenue $3.9M (-13.9% YoY); gross margin improved to 57.7%.
Operating expenses down 45.4% in first half; sales & marketing fell 69.2% in Q2 to $0.7M.
Cash and restricted cash $1.2M as of June 30, with net working capital $2.9M.
Merger with Vyome: all-stock deal; ReShape stockholders to own ~11.1% of combined company.
Asset sale to Biorad Medisys for $5.16M cash; assets include Lap-Band and Obalon systems.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.